menu search

Kymera therapeutics’ stat3 degrader kt-333 and irakimid degrader kt-413 demonstrate desired target knockdown and safety with continued dose escalation in ongoing phase i clinical trials

Data shared today on PK/PD and safety from additional KT-333 and KT-413 patient dose escalation cohorts show target knockdown at or near levels associ...

June 14, 2023, 6:30 am

Kymera therapeutics announces updated clinical data from the phase 1 trials of stat3 degrader kt-333 and irakimid degrader kt-413

Data shared today in abstracts from the International Conference on Malignant Lymphoma (ICML) Both programs continue to demonstrate substantial target...

June 9, 2023, 10:00 pm


Search within

Pages Search Results: